iBio, Inc. Common Stock Dividends
The next dividend date for iBio, Inc. Common Stock has not yet been scheduled.
What is a Dividend Date
When we talk about a dividend date, we’re referring specifically to the ex-dividend date.
This is the date on which all stockholders will earn a dividend. Technically, a person needs to be the owner of a share of stock as of the night before the ex-dividend date in order to earn the dividend.
The ex-dividend date is different than the date when the dividend is issued. Although you earn a dividend on the ex-dividend date, that dividend is typically not disbursed to your account until several weeks later.
Most brokerages will automatically credit the dividend to your account once it’s issued.
Historical Dividends for iBio, Inc. Common Stock (IBIO)
More About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2"expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Owning iBio, Inc. Common Stock Stock on the Dividend Date
If you own iBio, Inc. Common Stock stock on the ex-dividend date, then you earn the associated dividend.
Theoretically, the price of iBio, Inc. Common Stock stock should go down by the amount of the dividend (in addition to any other pressures that market forces have on the price of iBio, Inc. Common Stock stock).
Therefore, it is typically not expected that there is any incremental profit to be gained from buying iBio, Inc. Common Stock stock right before the ex-dividend date and then selling it immediately after. It’s not like you get the iBio, Inc. Common Stock dividend payout for free just by doing that since there is typically an equivalent commensurate drop in the stock price.
Learning More iBio, Inc. Common Stock Dividends
You can contact us any time if you would like to ask questions about iBio, Inc. Common Stock dividends or anything else related to the stock market.